Oppenheimer initiated coverage of Theravance Biopharma (TBPH) with an Outperform rating and $27 price target The firm sees potential for the company’s Phase 3 ampreloxetine readout in Q1 of 2026 to be “transformative.” It sees a positive risk/reward skew into the data. Oppenheimer’s 50% probability of success supports 50% share upside potential, and approval would likely support a roughly doubling of valuation expectations, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- These 3 Stocks Could Explode Higher, Say Five-Star Analysts – 11/28/2025
- Theravance Biopharma price target raised to $40 from $25 at BTIG
- Theravance Biopharma management to meet virtually with BTIG
- Theravance Biopharma’s Earnings Call Highlights Robust Growth
- Theravance Biopharma price target raised to $20 from $15 at H.C. Wainwright